A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer

Trial Profile

A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Alpelisib (Primary) ; Ribociclib (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Feb 2018 Planned primary completion date changed from 30 Apr 2019 to 31 May 2019.
    • 09 Dec 2017 Results (n=56) assessing safety and preliminary efficacy, presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top